Introduction {#s1}
============

Brain-derived neurotrophic factor (BDNF) is a key factor in neuroplasticity, synaptic function, and cognition. Due to its pleiotropic effects in the brain, BDNF has been implicated in cognitive functions as well as in the pathogenesis of various neuropsychiatric and neurodegenerative disorders ([@CIT0013]; [@CIT0040]; [@CIT0007]; [@CIT0027]). In particular, the human G196A polymorphism in the BDNF gene, which leads to a substitution of valine with methionine at codon 66 in the prodomain, has been thoroughly investigated for genetic associations with cognitive dysfunction, personality disorders, and neuropsychiatric and neurodegenerative disorders ([@CIT0014]; [@CIT0018]; see [@CIT0017]; [@CIT0045] for recent meta-analyses). However, although a number of studies found a significant correlation of the Val66Met polymorphism with select disorders, others were unable to replicate the findings. It has been suggested that these conflicting results may originate from confounding factors such as age, gender, environmental factors, sample size, ethnicity, and phenotype assessment ([@CIT0019]). In addition, it is likely that the complex genetic background present in human populations can contribute to this problem. The BDNF Val66Met knock-in mouse offers an opportunity to investigate the pathophysiological consequences of the presence of the polymorphism in a constant and reproducible genetic background ([@CIT0009]).

This knock-in mouse recapitulates the phenotypic hallmarks of the BDNF Val66Met human polymorphism. Indeed, both human and mice BDNF^Met^ allele carriers show reduced hippocampal volume, cognitive deficits, increased anxiety-related behaviour, and impaired extinction of fear conditioning, a type of learning involved in phobias and posttraumatic stress disorder ([@CIT0009]; [@CIT0015]; [@CIT0015]). It has been shown that BDNF^Met/Met^ mice display reduced regulated secretion of BDNF from hippocampal neurons, reduced dendritic arborization in the hippocampal dentate gyrus (DG), and reduced N-methyl-d-aspartate receptor-dependent synaptic plasticity in the hippocampus ([@CIT0009]; [@CIT0030]). Moreover, the binding of the BDNF transcript to the protein translin, required for mRNA export into dendrites, is disrupted by the presence of the Met mutation in the coding region of BDNF mRNA ([@CIT0011]). Accordingly, we proposed a hypothesis for the BDNF Val66Met-associated memory deficits as a model of impaired dendritic mRNA trafficking ([@CIT0004]).

The *bdnf* rodent gene is composed of at least eight untranslated 5' exons and one 3' exon encoding the protein, and different transcript isoforms are expressed by splicing each of the non-coding exons to the coding exon ([@CIT0001]; [Figure 1](#F1){ref-type="fig"}). The complex structure of the BDNF gene allows the distinct BDNF transcripts to be differentially modulated at subcellular locations, in specific brain regions, and in response to distinct stimuli ([@CIT0005]; [@CIT0029]). We have previously shown that BDNF mRNA variants are spatially segregated in response to neuronal activation within three subcellular compartments: the soma (BDNF variants 1, 3, 5, 7, 8, 9a), the proximal (BDNF 4) or the distal dendrites (BDNF 2, 6), thus behaving as a spatial code ([@CIT0002], [@CIT0005]). Moreover, we have also shown that BDNF-6 trafficking to dendrites is increased by physical exercise and chronic antidepressant treatments ([@CIT0003]), suggesting a role for a local increase of BDNF-6 mRNA at dendrites in the pro-adaptive effects of these two treatments. Of note, BDNF expression can also be altered by genetic and epigenetic regulations, including histone posttranslational modifications ([@CIT0026]). Accordingly, here we investigated whether the Val66Met mutation differentially affects the expression levels, epigenetic regulation, and dendritic trafficking of the different BDNF transcripts.

![Schematic representation of mouse BDNF (A) gene and ([B]{.ul}) transcripts structure. BDNF, brain-derived neurotrophic factor; CDS, coding sequence.](ijnppy_pyv069_f0001){#F1}

Methods {#s2}
=======

Animals {#s3}
-------

Male 3--4 month old BDNF^Met/Met^ and BDNF^Val/Val^ mice were used for all studies ([@CIT0009]). Mice were kept at 20--22°C on a 12h light/dark cycle (light on at 07:00 hours) with water and food available ad libitum. All animal handling and experimental procedures were performed in accordance with the European Community Council Directive 86/609/EEC and were approved by Italian legislation on animal experimentation (116/1992). All efforts were made to minimize animal distress and to reduce the numbers of animals used in this study.

RNA Isolation and Reverse Transcription {#s4}
---------------------------------------

Total RNA was extracted from hippocampi of BDNF^Met/Met^ and BDNF^Val/Val^ mice, using the RNeasy Lipid Tissue Mini Kit (Qiagen) according to manufacturer's instructions, and then quantified by absorption at A~260nm~, measured by UV spectrophotometry (NanoVue, GE Healthcare Europe GmbH). cDNA was synthesized from 1 μg of DNase-treated total RNA using a QuantiTect Reverse Transcription kit (Qiagen), following manufacturer's directions.

Quantitative Real-Time PCR {#s5}
--------------------------

Quantitative real time polymerase chain reaction (qPCR) analysis of mRNA expression levels was performed on a 7900HT Fast PCR System (Applied Biosystems by Life Technologies Italia) by using specific primers ([Table 1](#T1){ref-type="table"}) and QuantiFast SYBR Green master mix (Qiagen). All primers were as shown previously ([@CIT0020]). To measure the distinct BDNF transcripts, we designed one specific forward primer for each 5' exon and one common reverse primer in the 5' BDNF coding sequence. To measure BDNF-2, BDNF-7, and total BDNF mRNA, both forward and reverse primers were within the respective exon region. PCR cycling conditions were: 10min at 95°C, 40 cycles of 15 s at 95°C, and 1min at 60°C. Data from qPCR were normalized on the mean of two reference genes (β-actin and glyceraldehyde-3-phosphate dehydrogenase). An analysis of melting curve verified the specificity of the PCR products. Relative amounts were determined using the comparative Cq method ([@CIT0036]).

###### 

List and Sequence of Primers Used in This Study

  **Gene**             **Forward**                  **Reverse**
  -------------------- ---------------------------- -------------------------
  *BDNF-1* ^*a*^       CCTGCATCTGTTGGGGAGAC         CGCCTTCATGCAACCGAAGTAT
  *BDNF-2* ^*a*^       ACCTTTTCCTCCTCCTGCG          TGGATGAAGTACTACCACCTCGG
  *BDNF-3* ^*a*^       TGAGACTGCGCTCCACTCCC         CGCCTTCATGCAACCGAAGTAT
  *BDNF-4* ^*a*^       CAGAGCAGCTGCCTTGATGTTT       CGCCTTCATGCAACCGAAGTAT
  *BDNF-6* ^*a*^       ACAATGTGACTCCACTGCCGG        CGCCTTCATGCAACCGAAGTAT
  *BDNF-7* ^*a*^       ACTTACAGGTCCAAGGTCAACG       GGACAGAGGGTCGGATACAG
  *BDNF-8* ^*a*^       ATGACTGTGCATCCCAGGAGAAA      CGCCTTCATGCAACCGAAGTAT
  *Total BDNF* ^*a*^   TCGTTCCTTTCGAGTTAGCC         TTGGTAAACGGCACAAAAC
  *EZH2* ^*a*^         CAACCCTGTGACCATCCACG         CGACATCCAGGAAAGCGGTT
  *ß-actin* ^*a*^      GCCAGAGCAGTAATCTCCTTCT       AGTGTGACGTTGACATCCGTA
  *Gapdh* ^*a*^        CGTGCCGCCTGGAGAAACC          TGGAAGAGTGGGAGTTGCTGTTG
  ***ChIP***                                        
  *pBDNF-1* ^*b*^      TGATCATCACTCACGACCACG        CAGCCTCTCTGAGCCAGTTACG
  *pBDNF-2* ^*b*^      CCGTCTTGTATTCCATCCTTTG       CCCAACTCCACCACTATCCTC
  *pBDNF-3* ^*b*^      GTGAGAACCTGGGGCAAATC         ACGGAAAAGAGGGAGGGAAA
  *pBDNF-4* ^*b*^      CTTCTGTGTGCGTGAATTTGCT       AGTCCACGAGAGGGCTCCA
  *pBDNF-5*            GCTGAAGGCGTGCGAGTATT         GGCCGATATGTACTCCTGTTCTG
  *pBDNF-6* ^*b*^      ACTCACACTCGCTTCCTCCT         GCACTGGCTTCTCTCCATTT
  *pBDNF-7*            GGAAGGGTGGTGAGAGAGATATAGAG   GTGCCTAAGCCGGTGGTAAG
  *pBDNF-8*            TGAAAGGAAAAAGGAGAGGCTTT      AGAAAATGCCACTCCCACATAAG

^a^Primer sequences as in Ieraci et al. (2015).

^b^Primer sequences as in Tsankova et al. (2006).

BDNF, brain-derived neurotrophic factor; ChIP, chromatin immunoprecipitation; EZH2, enhancer of zeste homolog 2; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain reaction.

Chromatin Immunoprecipitation Assay {#s6}
-----------------------------------

Total hippocampi of 15 BDNF^Met/Met^ and 15 BDNF^Val/Val^ mice were used. Hippocampal tissue was cut into 1mm^3^ cubes and fixed in 1% formaldehyde at room temperature for 15min to cross-link protein to DNA. Reaction was stopped by adding glycine (125mM final concentration) for 5min. Tissue was homogenized in sodium dodecyl sulfate (SDS) nuclei lysis buffer (50mM Tris, pH 8.1, 10mM EDTA, 1% SDS; [@CIT0046]). Shearing of chromatin was performed with 13 cycles (20sec on, 40sec off) in a Microson sonicator (Misonix Inc.). Chromatin sonication sheared cross-linked DNA to the optimal size of 200--800 base pairs in length. Then, 150 µl chromatin was diluted 1:10 in chromatin immunoprecipitation (ChIP) dilution buffer (16.7mM Tris, pH 8.1, 1.2mM EDTA, 167mM NaCl, 1.1% Triton X-100, 0.01% SDS). ChIPs were performed by using the MagnaChIP kit (Merck Millipore), following manufacturer's instructions. Briefly, chromatin was immunoprecipitated at 4°C with 10 µg each of the following antibodies: anti-H3K27me3 (Merck Millipore, catalog \# 07-449), anti-acetyl histone H3 (acH3, Merck Millipore, catalog \# 06-599), or normal rabbit immunoglobulin G as control antibody (MagnaChIP kit, Merck Millipore). One hundredth of the pre-immunoprecipitated diluted chromatin was saved as input DNA for ChIP normalization. Immune complexes were sequentially washed with low salt immune buffer, high salt buffer, LiCl immune complex buffer, and Tris-EDTA buffer. Protein-DNA cross-links were reversed by heating at 62°C for 2 hours. After proteinase K digestion, DNA was purified by spin filter columns (MagnaChIP kit, Merck Millipore). To quantify histone-associated gene promoters, immunoprecipitated DNA samples were subjected to qPCR on a 7900HT Fast PCR System (Applied Biosystems) using gene-specific primers and QuantiFast SYBR Green (Qiagen). The primer sequences used were either de novo designed using Primer Express software (Applied Biosystems) or previously published elsewhere ([@CIT0044]). PCR cycling conditions were: 10min at 95°C, 40 cycles of 15 s at 95°C, and 1min at 60°C. DNA quantities were estimated from the quantification cycle (Cq) and then expressed as a percentage of corresponding input to normalize for differences in ChIP sample aliquots before immunoprecipitation. Briefly, percentage of input was calculated by 100 x 2^(Cq-adjusted\ Input\ ---\ Cq-enriched)^. Input DNA Cq was adjusted from 1% to 100% equivalent by subtracting 6.644 Cqs or Log~2~ 100. An analysis of melting curve verified the specifity of the PCR products.

Cell Cultures, 3-Deazaneplanocin A Treatment, and Short Interference RNA Transfection {#s7}
-------------------------------------------------------------------------------------

Mouse neuroblastoma N2A cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Euroclone), containing 10% fetal bovine serum (Euroclone) and 1% penicillin/streptomycin (Euroclone) at 37^o^C and 5% CO~2~. 3-deazaneplanocin A (DZNep) was purchased from Sequoia Research. DZNep was dissolved in distilled water and stored at -20°C.

For DZNep treatments, 2 x 10^5^ cells were seeded in six multiwell plates 24 hours before the treatments. DZNep was added to cell cultures with a range of concentration (0.5; 1 and 2 μM) and cells were harvested 24 hours later. RNA was extracted and processed for qPCR analysis.

For short interference RNA (siRNA) knock-down studies, N2A cells were transfected with EZH2 (GeneSolution siRNA 1027416, Qiagen) or scramble siRNA (Negative Control siRNA 1022076, Qiagen) according to the optimized protocol for N2A Cells (Amaxa Cell Line Nucleofector Kit V, Lonza). Briefly, 1 x 10^5^ cells were resuspended in 100 μl of Mouse NSC Nucleofector Solution containing 100nM of siRNA and nucleofected using the Program T-024 on an Amaxa Nucleofector II (Lonza). Cells were harvested 24 and 48 hours after transfection, and RNA was extracted and processed for qPCR analysis.

Pilocarpine Treatment {#s8}
---------------------

In order to measure dendritic targeting of BDNF by *in situ* hybridization and BDNF-2, BDNF-4, BDNF-6 and total BDNF mRNA expression, BDNF^Met/Met^ and BDNF^Val/Val^ mice were treated with pilocarpine (150mg/kg, i.p., Sigma-Aldrich) dissolved in 0.9% NaCl. To reduce peripheral cholinergic effects, mice were pre-treated with methylscopolamine (1mg/kg, i.p., Sigma-Aldrich) dissolved in PBS 20min before receiving pilocarpine. For the *in situ* hybridization experiment, six hours after pilocarpine administration, mice were anaesthetized with ketamine (100mg/kg, i.p., Sigma-Aldrich) and transcardially perfused with freshly made 4% paraformaldehyde (PFA, in PBS pH 7.3). The brains were then removed and kept in 4% PFA/20% sucrose (in PBS pH 7.3) at 4°C for at least 3 days before sectioning in 40 µm slices using a CO~2~-freezing microtome (Leica Microsystems). For BDNF transcripts expression, the vehicle groups were treated in sequence with PBS (as vehicle for methylscopolamine) and after 20min with saline (as vehicle for pilocarpine). Six hours after either vehicle or pilocarpine administration mice were sacrificed, their hippocampi were collected and RNA was extracted and processed for qPCR analysis.

*In Situ* Hybridization {#s9}
-----------------------

Five BDNF^Met/Met^ and five BDNF^Val/Val^ mice were used. *In situ* hybridization on free-floating 40 µm coronal brain sections cut at the level of the dorsal hippocampus was performed as described previously ([@CIT0041], [@CIT0042]). Specific probes against BDNF transcript containing BDNF-2, BDNF-4, or BDNF-6 were prepared from exon 2 nt 318--586 (Accession \#NM_001270631), exon 4 nt 703--901 (Accession \#X67107), or exon 6 nt 279--573 (Accession \#S71211) cloned in pBSKS vector as previously described ([@CIT0010]) using the DIG-RNA labeling kit according to manufacturer's instructions (Roche Diagnostics, Monza, Italy). Probe specificity for BDNF-2, BDNF-4, and BDNF-6 was previously demonstrated ([@CIT0010]). Hybridization with antisense probe was performed at 57°C followed by high stringency washes with 0.01X sodium saline citrate buffer containing 0.1% Tween-20 (SSCT) at 62°C. *In situ* hybridizations on brain sections from BDNF^Met/Met^ and BDNF^Val/Val^ mice were conducted in parallel. To obtain reproducible and comparable results and avoid saturation of the reaction, alkaline phosphatase development was always performed for 5h at room temperature. The use of non-radioactive *in situ* hybridization with digoxigenin-labeled probes for semi-quantitative evaluation of the *in situ* staining has been previously validated to study localization of dendritic mRNAs *in vivo* ([@CIT0039]; [@CIT0042]). In the present study, no saline-injected mice were included because in our previous work the BDNF^Met/Met^ and the BDNF^Val/Val^ mice differed in dendritic targeting of BDNF only following pilocarpine-induced neuronal activity, since in the basal condition BDNF mRNA is proximally confined ([@CIT0011]). In addition, we previously found no difference between saline-injected or naive animals regarding the distribution of total BDNF mRNA ([@CIT0042]) or exon 1, 2C, 4, and 6 mRNAs ([@CIT0010]).

Statistical Analysis for ChIP and qPCR {#s10}
--------------------------------------

For ChIP data, the percent input values from each data set were used in two-tailed unpaired *t*-tests to determine statistical significance. For mRNA data, fold changes relative to the respective control group (∆∆Cq method) were used in two-tailed unpaired *t*-tests (when two experimental groups were analyzed), in a Kruskal-Wallis test followed by Dunn' multiple comparison test (when more than two experimental groups were analyzed), or in a two-way ANOVA followed by Bonferroni's multiple comparison test (when the effect of the independent factors treatment and genotype were considered) to determine statistical significance. For all analyses, a value of *p* \< 0.05 was considered statistically significant. Statistical analysis of the data was carried out using GraphPad Prism4 (GraphPad Software).

Quantitative Image Analysis and Statistics {#s11}
------------------------------------------

Non-radioactive *in situ* hybridization was analyzed with a Nikon E800 microscope (X20 and X60 magnification, Nikon) and a CCD camera (DXM-1200, Nikon). Images were captured with a fixed illumination using a procedure described previously ([@CIT0042]) and analyzed with ImageJ ([@CIT0037]). Student's *t*-test was used for two-sample comparisons using the SigmaStat software (Systat Software).

Results {#s12}
=======

Expression of Splice Variants Containing BDNF-4 and BDNF-6 is Lower in BDNF^Met/Met^ Mice {#s13}
-----------------------------------------------------------------------------------------

We assessed the levels of BDNF mRNAs containing distinct transcripts of non-coding exons (BDNF-1 to BDNF-8) and total BDNF mRNA (all transcripts containing the coding exon 9) in the hippocampi of BDNF^Val/Val^ and BDNF^Met/Met^ mice. qPCR analysis showed lower levels of BDNF-4 (-20.45% vs. BDNF^Val/Val^; *p* \< 0.01) and BDNF-6 (-21.33% vs. BDNF^Val/Val^; *p* \< 0.05; [Figure 2](#F2){ref-type="fig"}) in BDNF^Met/Met^ mice, while no significant differences were observed for the other BDNF variants ([Figure 2](#F2){ref-type="fig"}). Interestingly, levels of total BDNF showed a trend toward reduction, although this was not statistically significant (-14.88%; *p* = 0.054; [Figure 2](#F2){ref-type="fig"}). BDNF-5 transcript levels were very low in both BDNF^Val/Val^ and BDNF^Met/Met^ mice, which did not allow a reliable measurement of these mRNAs (not shown).

![Reduced expression of brain-derived neurotrophic factor (BDNF) transcripts in BDNF^Met/Met^ mice. BDNF transcript expression levels were analyzed by quantitative real-time PCR (qPCR). BDNF^Met/Met^ mice showed lower levels of BDNF-4 and BDNF-6 compared to BDNF^Val/Val^ mice. Expression levels were normalized to β-actin and Gapdh and expressed as a percentage relative to BDNF^Val/Val^ mice. Data are presented as mean ± standard error of the mean (n= 6 independent biological replicates). Student's *t*-test, \**p* \< 0.05, \*\**p* \< 0.01.](ijnppy_pyv069_f0002){#F2}

Lys27 Trimethylation of H3 Histone at Select BDNF Promoters is Higher in Hippocampus of BDNF^Met/Met^ Mice {#s14}
----------------------------------------------------------------------------------------------------------

To understand whether epigenetic changes are involved in BDNF expression in mice carrying the BDNF Val66Met polymorphism, we investigated the regulation of chromatin architecture at different BDNF promoters. To this aim, we used ChIP assay combined with qPCR to assess levels of acH3 and H3K27me3 at promoters of all non-coding BDNF transcripts (BDNF-1 to -8). AcH3 and H3K27me3 are known markers of transcriptional activation and repression, respectively ([@CIT0044]). AcH3 was unchanged for all BDNF promoters ([Table 2](#T2){ref-type="table"}). Instead, we found significantly higher level of H3K27me3 at BDNF-5 (*p* \< 0.005), BDNF-6 (*p* \< 0.005), and BDNF-8 (*p* \< 0.05) promoters in BDNF^Met/Met^ compared to BDNF^Val/Val^ mice ([Table 2](#T2){ref-type="table"}). These results show that reduced expression of BDNF-6 in BDNF^Met/Met^ mice may be accounted for by this epigenetic change at the corresponding promoter. No changes were found at the BDNF-4 promoter, although expression of the corresponding transcript was reduced in BDNF^Met/Met^.

###### 

Levels of Occupancy of acH3 and H3K27me3 at BDNF Gene Promoters

  **Gene promoter**   **BDNF** ^**Val/Val**^   **BDNF** ^**Met/Met**^   *p* **-value**
  ------------------- ------------------------ ------------------------ ----------------
  ***acH3***                                                            
  *pBDNF-1*           0.430±0.0996             0.572±0.1044             0.3819
  *pBDNF-2*           0.219±0.0252             0.339±0.0447             0.0799
  *pBDNF-3*           0.442±0.0834             0.697±0.1766             0.2616
  *pBDNF-4*           0.491±0.0478             0.493±0.0938             0.9858
  *pBDNF-5*           0.517±0.0668             0.673±0.1110             0.2948
  *pBDNF-6*           0.812±0.0888             1.059±0.0698             0.0946
  *pBDNF-7*           0.874±0.1258             1.118±0.1974             0.3561
  *pBDNF-8*           0.099±0.0249             0.1323±0.0313            0.4561
  ***H3K27me3***                                                        
  *pBDNF-1*           3.250±0.3227             3.717±0.3250             0.3658
  *pBDNF-2*           3.658±0.1721             4.487±0.3230             0.0861
  *pBDNF-3*           3.555±0.4545             4.374±0.5488             0.3143
  *pBDNF-4*           3.196±0.2194             3.300±0.4021             0.8321
  *pBDNF-5*           2.421±0.0428             3.156±0.079              0.0012**\***
  *pBDNF-6*           3.954±0.0832             4.543±0.0557             0.0042**\***
  *pBDNF-7*           2.992±0.1374             3.657±0.574              0.0851
  *pBDNF-8*           1.645±0.1478             2.331±0.079              0.0150**\***

Data are expressed as percentage of input and presented as mean ± standard error of the mean. Student's *t*-test. \*significant difference.

BDNF, brain-derived neurotrophic factor.

EZH2 Modulates BDNF Gene Expression {#s15}
-----------------------------------

H3K27 di- and trimethylation, epigenetic modifications leading to chromatin condensation and transcriptional repression, are mediated by the multiprotein complex Polycomb Repressive Complex 2 ([@CIT0031]; [@CIT0025]). The minimum core components necessary for the catalytic activity *in vitro* are EZH2, embryonic ectoderm development, and suppressor of zeste 12, with EZH2 being the actual histone methyltransferase in K27 trimethylation ([@CIT0022]). EZH2 has been involved in epigenetic reprogramming related to carcinogenesis ([@CIT0008]; [@CIT0012]). To understand whether EZH2 is able to modulate the transcription of either total BDNF mRNA or BDNF-6 transcript, we selectively down-regulated EZH2 expression *in vitro* using siRNA. Nucleofection of EZH2 siRNA in N2A neuroblastoma cells resulted in about 79.10±1.35% (*p* \< 0.01) and 54.36±3.37% (*p* \< 0.05) EZH2 mRNA reduction after 24 and 48 hours, respectively ([Figure 3A](#F3){ref-type="fig"}). This reduction of EZH2 was accompanied by up-regulation of total BDNF of 54.10±15.53% (*p* \< 0.05) and 48.50±13.18% (*p* \< 0.01) after 24 and 48 hours, respectively ([Figure 3A](#F3){ref-type="fig"}). At the same time points, the increase of BDNF-6 revealed a significant difference only after 48 hours (12.10±3.95%; *p* \< 0.05; [Figure 3A](#F3){ref-type="fig"}).

![Modulation of total brain-derived neurotrophic factor (BDNF) and BDNF-6 expression by EZH2. (A) Knockdown of EZH2 in N2A cells reduced expression of EZH2 (left panel). Knockdown of EZH2 induced up-regulation of total BDNF mRNA 24 and 48 hours after the nucleofection, and up-regulation of BDNF-6 after 48 hours (central and right panels). Expression levels were normalized to β-actin and Gapdh and results were expressed as mean ± standard error of the mean (SEM; n = 5 independent biological replicates). \**p* \< 0.05; \*\**p* \< 0.01 compared to scramble siRNA (SCR) by Student's *t*-test. (B) mRNA levels of total BDNF and BDNF-6 in N2A cells were increased after 24 hours of treatment with 3-deazaneplanocin A (DZNep) at 0.5, 1, and 2 μM. Expression levels were normalized to β-actin and Gapdh and results are expressed as mean ± SEM (n = 5--6 independent biological replicates). \**p* \< 0.05; \*\**p* \< 0.01 compared to vehicle (VEH) by Kruskal-Wallis test followed by Dunn's multiple comparison test.](ijnppy_pyv069_f0003){#F3}

To further confirm the role of EZH2 in the regulation of BDNF gene expression, N2A cells were treated with different concentrations of DZNep, which has been shown to deplete and inhibit EZH2 ([@CIT0021]). DZNep increased the expression of both total BDNF and BDNF-6, with the higher response observed at 1 μM (total BDNF: 77.50±22.79% of Veh; BDNF-6: 34.70±9.22% of Veh; *p* \< 0.01; [Figure 3B](#F3){ref-type="fig"}). Therefore, the present results show that EZH2 may modulate BDNF transcription through H3K27 methylation.

BDNF-6 Dendritic Trafficking is Impaired in Hippocampi of BDNF^Met/Met^ Mice {#s16}
----------------------------------------------------------------------------

The splice variants containing BDNF-2, BDNF-6, and, to a lesser extent, BDNF-4, are the main ones targeted to dendrites in hippocampal neurons upon activation ([@CIT0002], [@CIT0005]). We have previously shown that trafficking of total BDNF in dendrites upon pilocarpine treatment is abolished in the CA1 and CA3 hippocampal areas of BDNF^Met/Met^ mice ([@CIT0011]). Therefore, in the present study we sought to assess whether pilocarpine-induced dendritic targeting of these mRNA variants was also reduced in BDNF^Met/Met^ mice. We employed *in situ* hybridization to measure intracellular BDNF-2, BDNF-4, and BDNF-6 mRNA after pilocarpine stimulation in the CA1, CA3, and DG areas of the hippocampi of both mouse genotypes, as done previously for total BDNF mRNA ([@CIT0011]; [Figure 4A](#F4){ref-type="fig"}--[C](#F4){ref-type="fig"}). *In situ* hybridization experiments were carried out at 6h post-pilocarpine because BDNF mRNA targeting in CA3 is at a maximum at this time in rodents ([@CIT0042]) and CA3 is the region where the deficit in BDNF mRNA targeting is at a maximum in BDNF^Met/Met^ mice ([@CIT0011]).

![Reduced BDNF-6 dendritic targeting in BDNF^Met/Met^ mice after pilocarpine treatment. High-magnification pictures of the *in situ* hybridization and densitometric analysis of dendrites at progressive distances from soma for: (A) BDNF2-mRNA, (B) BDNF-4, and (C) BDNF-6 mRNAs in mouse hippocampal CA1, CA3, and dental gyrate (DG) regions of BDNF^Val/Val^ and BDNF^Met/Met^ mice. Data are expressed by the gray level of the staining; the distance is expressed in µm from the point of emergence of the apical dendrites from the soma (=0 µm), and the bar represents the mean ± standard error of the mean (n= 5 independent biological replicates). \**p* \< 0.05; \*\**p* \< 0.01. d.rad, distal radiatum; IML, inner molecular layer; lac.mol, lacunosum molecular layer; MML, medial molecular layer; OML, outer molecular layer; p.rad, proximal radiatum; s.gr, stratum granularis; s.luc, stratum lucidum; s.pyr, stratum pyramidale.](ijnppy_pyv069_f0004){#F4}

Densitometric analysis of *in situ* labeling, to measure the labeling intensity at different distances from the cell body layer, showed no differences in BDNF-2 subcellular localization in all three areas of the hippocampi in BDNF^Met/Met^ mice with respect to BDNF^Val/Val^ ([Figure 4A](#F4){ref-type="fig"}). However, for BDNF-4, a significant reduction was found in the stratum pyramidale of CA1 and CA3 ([Figure 4B](#F4){ref-type="fig"}), while no changes were found in the other laminas. BDNF-6 mRNA labeling was significantly reduced in BDNF^Met/Met^ mice in the proximal and distal stratum radiatum of both CA1 and CA3 ([Figure 4C](#F4){ref-type="fig"}). No difference in pilocarpine-induced BDNF-6 trafficking was found in DG between the two genotypes. These results showed that the reduced trafficking of BDNF mRNA in hippocampal areas, previously found in BDNF^Met/Met^ mice ([@CIT0011]), is accounted for mostly, if not exclusively, by BDNF-6 containing splice variant.

Pilocarpine has been shown to induce BDNF mRNA expression ([@CIT0033]; [@CIT0005]), and since defective dendritic trafficking of BDNF transcripts could be due in principle to changes in either the trafficking mechanism or expression or both, we also sought to investigate whether expression of BDNF-2, BDNF-4, BDNF-6, and total BDNF were altered by pilocarpine treatment, in both genotypes. We found that pilocarpine increased the expression of BDNF-2, BDNF-4, and total BDNF similarly in both BDNF^Val/Val^ and BDNF^Met/Met^ mice ([Figure 5A](#F5){ref-type="fig"}, [B](#F5){ref-type="fig"}, and [D](#F5){ref-type="fig"}), but did not affect significantly the expression of BDNF-6 ([Figure 5C](#F5){ref-type="fig"}). Therefore, our present and previous results combined show that impaired trafficking of BDNF-6 in BDNF^Met/Met^ mice is not due to reduced expression but to a selective defect in translocation.

![Expression of BDNF-6 is not altered by pilocarpine. (A) Pilocarpine treatment increased BDNF-2 expression levels in the hippocampi of BDNF^Val/Val^ and BDNF^Met/Met^ mice \[two-way ANOVA, treatment effect: F~(1,19)~ = 13,83, *p* = 0.0015; genotype effect: F~(1,19)~ = 0,02023, *p* = 0,8884; interaction: F~(1,19)~ = 1,289e-005, *p* = 0,9972\]. (B) Pilocarpine treatment increased BDNF-4 expression levels in the hippocampi of BDNF^Val/Val^ and BDNF^Met/Met^ mice \[two-way ANOVA, treatment effect: F~(1,18)~ = 11.31, *p* = 0,0035; genotype effect: F~(1,18)~ = 0,0538, *p* = 0,8192; interaction: F~(1,18)~ = 0,00645, *p* = 0,9369\]. An additional post hoc analysis with Student's *t*-test confirmed lower BDNF-4 levels in BDNF^Met/Met^ vs. BDNF^Val/Val^ mice (*p* = 0.0325). (C) BDNF-6 expression levels were analyzed by quantitative real-time PCR (qPCR) in the hippocampi of BDNF^Val/Val^ and BDNF^Met/Met^ mice. Treatment with pilocarpine did not modify BDNF-6 levels \[two-way ANOVA, treatment effect: F~(1,19)~ = 0,4259, *p* = 0,5218; genotype effect: F~(1,19)~ = 1.870, *p* = 0,1874; interaction: F~(1,19)~ = 0,1794, *p* = 0,6767\]. An additional post hoc analysis with Student's *t*-test confirmed lower BDNF-6 levels in BDNF^Met/Met^ vs. BDNF^Val/Val^ mice (*p* = 0.0309). (D) Pilocarpine treatment increased total brain-derived neurotrophic factor (BDNF) expression levels in the hippocampi of BDNF^Val/Val^ and BDNF^Met/Met^ mice \[two-way ANOVA, treatment effect: F~(1,18)~ = 11.93, *p* = 0,0028; genotype effect: F~(1,18)~ = 0,1005, *p* = 0,7548; interaction: F~(1,18)~ = 0,1471, *p* = 0,7059\]. Expression levels were normalized to β-actin and Gapdh and expressed as a percentage relative to BDNF^Val/Val^ control mice. Data are presented as mean ± standard error of the mean (n= 5--7 independent biological replicates). Two-way ANOVA of vehicle (Veh) groups vs. pilocarpine treated (Pilo) groups followed by Bonferroni's multiple comparison test (\**p* \< 0.05 compared to respective vehicle group) or Student's *t*-test (^\#^ *p* \< 0.05 compared to BDNF^Val/Val^ vehicle).](ijnppy_pyv069_f0005){#F5}

Discussion {#s17}
==========

BDNF has been implicated in the pathophysiology of brain disorders as well as in the action of therapeutic drugs, particularly antidepressants. We have previously reported that different BDNF transcripts code for different neuronal localization of BDNF ([@CIT0010]), and that BDNF-6 is the major BDNF transcript targeted to dendrites upon neuronal activation ([@CIT0002], [@CIT0005]). More recently, we have shown that physical exercise and chronic antidepressant treatments not only increase BDNF expression in rodent hippocampi, but also enhance targeting of BDNF mRNA in hippocampal dendrites, and that this increased trafficking is accounted for by the BDNF-6--containing splice variant ([@CIT0003]; [@CIT0020]).

The results of the present work can be summarized as follows: (1) homozygous mice carrying the human BDNF Val66Met polymorphism of BDNF (BDNF^Met/Met^) display repressive epigenetic changes (increased H3K27me3) at BDNF promoters 5, 6, and 8; (2) the repressive epigenetic change at the BDNF-6 promoter is accompanied by reduced transcription of BDNF-6; (3) neuronal activation--induced trafficking of BDNF-6 is also impaired in BDNF^Met/Met^ mice. This impairment is not due to reduced BDNF-6 expression, but to a defect in translocation.

In a recent genome-wide (ChIP-Seq) analysis we found differential epigenetic changes in a large number of gene promoters of BDNF^Met/Met^ versus BDNF^Val/Val^ mice ([@CIT0032]; ms. in preparation). Here we show that the presence of the human polymorphism also induces epigenetic changes in the BDNF gene itself. In particular, we have found an increase of the H3K27me3 level at the BDNF-6 promoter, consistent with the decrease of BDNF-6 transcript expression. Moreover, in cell cultures we have shown that RNA silencing or pharmacological inhibition of EZH2, the methyltransferase that induces histone H3 trimethylation of Lys 27, increased the expression of total BDNF and BDNF-6 transcripts. These results are in line with recent data showing that EZH2 increases the amount of H3K27me3 at BDNF promoters and decreases BDNF expression in endothelial cells and primary cortical neurons, indicating a possible common mechanism of BDNF regulation in different cell types ([@CIT0034]; [@CIT0028]). The present results strongly suggest that increased H3K27me3 induces transcriptional repression of BDNF-6, although additional epigenetic changes may be involved. We have measured the expression of total BDNF in the hippocampi of BDNF^Met/Met^ mice and found no significant changes (although a trend for reduction was found), in agreement with previous studies comparing BDNF^Val/Met^ and BDNF^Met/Met^ mice ([@CIT0023]; [@CIT0049]). This lack of effect of the Val/Met polymorphism on total BDNF may suggest that the reduction in expression of BDNF-4 and BDNF-6 splice variants is not enough to significantly reduce the total expression of BDNF (including all splice variants). However, it is noteworthy that, although total BDNF mRNA was found to be unchanged in BDNF^Met^ allele carrier mice, the BDNF protein has been previously found to be significantly reduced in both BDNF^Val/Met^ and BDNF^Met/Met^ mice ([@CIT0023]; [@CIT0006]; [@CIT0049]).

In the present study (except for BDNF-6) we often found a lack of correlation between expression levels of transcripts and epigenetic changes at corresponding promoters. For instance, we found a lower expression of BDNF-4 in BDNF^Met/Met^ mice, although no changes were found in H3 histone modifications. Also, differently from BDNF-4 and BDNF-6, we found no changes in the expression of BDNF-8 in BDNF^Met/Met^, although this promoter showed increased K27 trimethylation of associated H3 histone. However, the level of expression of a gene is the combinatorial result of several epigenetic changes. It is not surprising to find a lack of correlation between a single histone mark at the gene promoter and expression levels of the corresponding gene (see [@CIT0043]). It is possible that additional epigenetic changes regulate transcription of BDNF-8, explaining why in this case there is no direct correspondence between increased H3K27 trimethylation and reduced transcription.

We have previously shown that dendritic targeting of total BDNF is defective in BDNF^Met/Met^ mice ([@CIT0011]). Interestingly, as shown here, BDNF^Met/Met^ mice display a selective impairment of BDNF-6 targeting to dendrites in the CA1 and CA3 hippocampal areas. Combined with our previous results, showing that increased BDNF dendritic trafficking induced by physical exercise and chronic antidepressants is accounted for by BDNF-6 ([@CIT0003]), the present results suggest a crucial role for BDNF-6 in mediating some effects of the neurotrophin at synaptic locations. It can be envisaged that defective dendritic targeting of BDNF mRNA in BDNF^Met/Met^ mice is mainly due to changes in BDNF-6. Of note, we found that at 6h post-pilocarpine treatment, BDNF-2 mRNA was not detectable in hippocampal laminas containing dendrites either in BDNF^Val/Val^ or in BDNF^Met/Met^ mice. This finding suggests that BDNF-2 mRNA targeting may have a different time-course with respect to BDNF-6.

The present findings add to the significance of the BDNF Val66Met knock-in mice as an interesting model that recapitulates several aspects of neuropsychiatric pathology ([@CIT0015]). Reduced expression and dendritic targeting of BDNF-6 could be a causal factor for reduced regulated release of BDNF at synapses, found in this knock-in mouse ([@CIT0009]).

It is not known how the presence of the BDNF polymorphism may affect epigenetic regulation of BDNF transcription. At present, a likely explanation is that BDNF and other neurotrophins are capable of regulating their own transcription ([@CIT0024]; [@CIT0047]; [@CIT0048]). This regulation is selective for different BDNF transcripts, as we have shown previously ([@CIT0029]). Reduced availability of BDNF at synapses may in turn contribute to reduced dendritic development and hippocampal volume, which are recognized features of BDNF Val66Met knock-in mice. This could be a distinct feature of pathology not only in mice, but also in humans carrying the BDNF Val66Met polymorphism that display reduced hippocampal volume ([@CIT0016]). In addition, because dendritic targeting of BDNF-6 is involved in the antidepressant mechanism ([@CIT0003]), the impairment of this mechanism in BDNF^Met/Met^ mice could be a reason for the lack of response to selective serotonin reuptake inhibitors in these mice ([@CIT0009]; [@CIT0006]).

It has been proposed that dysfunction in the glutamate system, including altered glutamate release/transmission, clearance, and metabolism, has a central role in neuropsychiatric pathophysiology ([@CIT0035]). BDNF has a crucial role in the regulation of transmission and plasticity at glutamate synapses, and BDNF^Met/Met^ mice have been shown to have impaired synaptic plasticity in the hippocampus ([@CIT0030]). Further studies are warranted to investigate the effects of BDNF-6 overexpression or silencing on synaptic function and behavior, as well as on the response to stress. It will also be interesting to assess the behavioral and cellular/molecular effects of chronic antidepressants or physical exercise in Val66Met knock-in mice, considering the specific influence exerted by these environmental factors on BDNF-6 expression and targeting ([@CIT0003]) and its ability to modify the number of dendritic branches in the distal portion of the dendritic arbor ([@CIT0002]).
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